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Abstract
MircoRNAs (miRNAs) are small non-coding RNAs that govern the gene expression and, play significant role in the
pathogenesis of heart failure. The detection of miRNAs in circulation of pulmonary hypertensive (PH) human subjects
remains elusive. In the current study, we determined the pattern of miRNAs of mild-to-severe human PH subjects and,
compared them with the control subjects by miRNA array. Blood was obtained using fluoroscopic and waveform guided
catheterization from the distal (pulmonary artery) port of the catheter. A total 40 human subjects were included in the study
and, the degree of PH was determined by mean pulmonary arterial pressure. Among several miRNAs in the array, we
validated 14 miRNAs and, the data were consistent with the array profile. We identified several novel downregulated
miRNAs (miR-451, miR-1246) and upregulated miRNAs (miR-23b, miR-130a and miR-191) in the circulation of PH subjects.
Our study showed novel set of miRNAs which are dysregulated in PH and, are directly proportional to the degree of PH.
These miRNAs may be considered as potential biomarker for early detection of PH.
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Introduction
MicroRNAs (miRNAs) are small, endogenously expressed
noncoding RNAs that regulate gene expression at post-transcrip-
tional level, via degradation or translational inhibition of their
target mRNAs [1,2]. MiRNAs are <22 nucleotides in length
which bind to the 39 untranslated region of specific target genes
and thereby suppress/inhibit the translation of target genes.
Functionally, an individual miRNA can regulate the expression of
multiple target genes [3,4]. Although, the exact mechanism is
unclear, it is reasonable to accept a ‘‘seed region’’ of 3 to 8
nucleotide of miRNA might be accountable for the interaction [3].
Pulmonary hypertension (PH) is a progressive pulmonary
vascular disease with high morbidity and mortality. PH results in
right ventricular hypertrophy (RVH), progressive fibrosis and RV
failure; and low cardiac output leading to increase morbidity, and
mortality [5,6]. In the clinical setting, the disease is often detected
in later stages marked by full-blown RV failure and, the treatment
regimen is limited that includes the use of prostaglandin analogues,
endothelin receptor antagonist and PDE5 which works primarily
in the vasculature as a vasodilator and anti-proliferative [7,8,9].
The pathological manifestation of PH is remodeling of pulmonary
arteries which increased proliferation of pulmonary artery smooth
muscle cells and dysfunction of pulmonary artery endothelial cells
resulting gross vascular remodeling. There is accumulating
evidence for the critical role of miRNA in diverse cardiovascular
remodeling that include development, vessel wall homeostasis,
angiogenesis and vascular injury [10,11], but, the miRNA
profiling in vascular diseases are limited.
Recent studies have shown that miRNAs are circulating freely
in the mammalian blood and can be predicted as ‘‘biomarker’’ for
early diagnosis of acute myocardial infarction and heart failure in
humans [12,13,14,15,16,17]. The molecular mechanism of
presence of stable miRNA in the circulation is currently elusive.
However, several evidences suggest that miRNAs are secreted as
micro vesicles or exosome and apoptotic bodies that may be
responsible for release the miRNAs into the circulation
[18,19,20,21] and, are extremely stable in the blood or serum
[22]. Although, recent studies identified circulatory miRNA in
coronary artery disease [23,24], but, the signatory profile of
miRNAs is not established in human PH subjects. Identification of
circulatory miRNAs in PH subjects may provide a novel
therapeutic intervention opportunity. The objective of this study
is to identify the miRNA(s) signature in circulation of human PH
subjects. This study is the first to identify novel miRNAs in human




The patients were visited at Scott & White Hospital, Temple,
TX with PH diagnosed by right heart cath. The consent was
obtained from all participants before enrolled in this study. Forty
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consecutive patients undergoing right heart catheterization for
diagnosis of pulmonary hypertension or monitoring of disease
progression and response to therapy were enrolled in the study.
The study protocol was approved by the ethics committee of Scott
& White Hospital that conforms to the principles outlined in the
Declaration of Helsinki. All clinical samples were obtained with
approval of the Scott & White Hospital research ethics commit-
tees. The written consents were obtained from each patient for this
study and were kept on file. The consent procedure was approved
by S & W Ethics’ committee. The protocol (#100029) was
approved by the Scott & White Healthcare Institutional Review
Board.
After fluoroscopic and waveform guided catheterization of the
pulmonary artery, approximately 20 ml of blood was obtained
from the distal (pulmonary artery) port of the catheter with the
balloon deflated. The blood was then injected into purple top
tubes and transported to the laboratory for processing as described
below.
Patient characteristics are summarized in table 1. The patients
were stratified as having mild, moderate, or severe PH on the basis
of mean pulmonary artery pressure. Using a cutoff of 40 mmHg
and above for severe disease, 35 mmHg and above for moderate
disease and above 25 mmHg for mild disease, 16 patients were
identified as severe, 15 patients were considered as moderate and,
1 was excluded due to right heart failure. In this group, disease
severity correlated with PVR, RAP, RVSP, and RVID (Figure 1).
The remaining 8 were defined as controls on the basis of normal
resting hemodynamics. Additionally, we have included 8 more
healthy subjects in control group for validation of selected miRNA
analysis. This group of patients had undergone catheterization to
rule out PH as a cause of dyspnea. The classification was based
with pulmonary hypertension World Health Organization (WHO)
clinical classification system (Dana Point 2008). The PH has been
defined as an increase in mean pulmonary arterial pressure (PAP)
.25 mmHg at rest as assessed by right heart catheterization
(RHC) as per the guidelines for diagnosis and treatment of
pulmonary hypertension as described [25]. This value has been
used for selecting patients in this study. It is of note that our sample
population is a heterogeneous in nature. But, in our patient group,
we observed that all had elevated mean PAP and were associated
with the symptoms of pulmonary hypertension as per the
guidelines of WHO clinical classification. Of the patients with
pulmonary hypertension, 11 were diagnosed with revised (Dana
Point) group 1 disease or pulmonary arterial hypertension. 7 were
diagnosed with group 2 PH showing to left sided cardiac
dysfunction, 8 were diagnosed with group 3 PH owing to
structural lung disease, and 1 was diagnosed with group 4 PH
secondary to chronic thromboembolic disease. A detailed diag-
nostic parameters and associated condition of PH subjects are
shown in Supporting Information S1.
Of the patients included in group 1, 4 were treatment naı¨ve, 3
were taking calcium channel blockers alone, 2 were taking
sildenifil and ambrisentan, 1 was taking bosentan and calcium
channel blockers, and 1 was taking tadalafil and calcium channel
blockers.
The miRNA array was performed using the PH subject whose
mean PAP was 53 mm Hg and diagnosed as idiopathic pulmo-
nary hypertensive patient. The samples we validated in our cohort
study were considered as pulmonary hypertensive. However, these
subjects were also exhibited symptoms associated with PH like
COPD, interstitial lung disease, obstructive lung disease, sclero-
derma, etc. There was no morbidity occurs so far in this study
group; therefore, we believe that the changes of miRNA in the
blood were associated with PH.
During the right heart catheterization, approximately twenty
milliliters of blood were obtained from the pulmonary artery,
processed and, the buffy coats were prepared and were stored at
280uC.
MiRNA isolation
The miRNA was isolated using the PH subject whose mean
PAP was 53 mmHg and diagnosed as idiopathic pulmonary
hypertensive patient. The control subjects miRNA was isolated
from the subjects whose mean PAP was 20 mmHg. Isolation of
miRNA was done using miRNeasy Mini Kit (Qiagen, California,
USA) as per manufacturer’s instructions. Briefly, Twenty milliliters
of blood were collected from study subjects in PAXgene Blood
RNA tubes (BD, USA). The buffy coats (250 mL each) were
homogenized in 700 mL of QIAzol lysis reagent. After addition of
140 mL chloroform, the homogenate was separated into aqueous
and organic phases by centrifugation. The upper aqueous phase
(approximately 320 mL) containing the RNA was extracted, and
100% ethanol (approximately 525 mL) was added to provide
appropriate binding conditions for all RNA molecules from 18
nucleotides (nt) upwards into the miRNeasy columns. This was
then applied to the RNeasy Mini spin column, where the total
RNA was bound to the membrane and phenol and other
contaminants were washed away by washing with the wash buffer
(700 ml Buffer RWT) and subsequently, twice with 500 ml of Buffer
RPE. Total microRNA was then eluted in 20 mL RNase-free
water.
Microarray processing and Analysis
RNA was quantified and assessed using the RNA 6000 Nano
Kit and 2100 Bio analyzer (Agilent Technologies UK Ltd, West
Lothian, UK). MiRNA array was performed and analyzed by LC
Bioscience, Austin, TX, USA. In brief, this analysis was performed
on the Agilent miRNA array, using the labeling kit, reagents and
methods recommended by the manufacturer. Samples for miRNA
profiling studies were processed by LC Bioscience (Austin, TX),
according to standard operating procedures in the GLP-compliant
services laboratory. Total RNA is first dephosphorylated and then
the pCp-Cy3 labeling molecule is ligated to the 39 ends of the
RNA molecules. The labeled RNA is purified using BioSpin6 (Bio-
Rad, Hercules CA). Hybridization, washing, staining, imaging,
and signal extraction were performed according to Agilent-
recommended procedures. The data represent as log2 value.
Paired t-test or ANOVA were performed to find statistically
significant difference between the groups and p,0.05 was
considered as a significant.
Average values of the replicate spots of each miRNA on the
microarray were normalized using global normalization. The
correction factor was calculated by dividing the sum of intensities
of each sample by the average of all the samples. The normalized
values were calculated by multiplying average intensities of each
miRNA with the correction factor. The JMP 6.0.0 software (SAS
Institute Inc., Cary, NC) was used for hierarchical clustering,
generation of heat maps, and principal component analysis (PCA).
The miRNA array data is MIAME compliant has been submitted
to the Gene expression Omnibus server at NCBI vide GEO no
GSE4415.
Complementary 1st strand-DNA synthesis and
quantitative real-time PCR
The samples we validated in our cohort study were considered
as pulmonary hypertensive. However, these subjects were also
exhibited symptoms associated with PH like COPD, interstitial
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lung disease, obstructive lung disease, scleroderma, etc. There was
no morbidity occur so far in this study group, therefore, we believe
that the changes of miRNA in the blood were associated with PH.
To confirm the miRNA array data, we performed a qRT-PCR
using buffy coat. A total of 40 samples were studied as a cohort
basis. Two hundred nano-grams of each subjects RNA enriched
for small species with length ,200 bases were reverse-transcribed
into first strand cDNA using an RT2 miRNA First Strand Kit (SA
Biosciences, Frederick, MD). The cDNA was mixed with RT2
SYBR Green/ROX qPCR Master Mix and the mixture was
added to individual specific primers and, has- miR-U6 (House-
keeping micro-RNA) as per manufacturer’s instruction in technical
duplicates. PCR was performed on a Stratagene MX 3005 Real-
Time PCR System (Stratagene, CA). The following thermal cycle
was used 95uC, 10 min, 40 cycles of (95uC, 15 sec; 60uC, 40 sec;
72uC, 30 sec). ROX was used as internal reference dye.
Data Analysis
Threshold cycle (Ct) for each miRNA was extracted using
MXPro software (Stratagene) by setting threshold and automat-
ically defined baseline. The raw Ct was normalized using the
quintile method to remove the variations from the housekeeping
genes. The fold change for each miRNA was calculated using
DDCt method. The data for the expression of these miRNAs was
normalized to 106 copies of housekeeping has-miR-U6. If the
expression of miRNAs of interest showed a copy number of #1
per 104 copies of has-miR-U6, it was termed as ‘‘not detected.’’
Statistical Analysis
Statistical analyses were performed using GraphPad Prism 5.0
statistical package for Windows (GraphPad Software Inc., La Jolla,
CA). Data are presented as mean 6 SEM unless indicated
otherwise and, plasma miRNA levels are presented as fold-change
relative to the healthy subjects. Linear regression analyses were
used to correlate quantitative variables after normalization of non-
Gaussian variables by log transformation. Comparisons between 2
groups were performed using Student t tests for Gaussian data or
Mann-Whitney tests for non-Gaussian data. The P-value (P,0.05)
was considered as statistically significant differences between the
two groups. Results were also analyzed by one-way ANOVA for
Figure 1. Characterization of human PH patients profiles. A. The PAM, PAS and PAD were determined by catheterization as described in
material and methods. B. Determination of profiles for pulmonary vascular resistance (PVR), C. Right atrial pressure (RA), D. Right ventricular systolic
pressure (RVSP), E. Right ventricular internal diameter (RVID) and F. Ejection fraction (EF). Data represent means 6 SEM. N= 8 for control, 15 for
moderate PH and 17 for severe PH group. *denotes p,0.001 and ** denotes p,0.05 compared to the healthy subjects, n.s. is non-significant.
doi:10.1371/journal.pone.0064396.g001
Table 1. The one-way ANOVA was performed to determine
the significance level among the groups.
Control Moderate PH Severe PH P value
PAM (mm of Hg) 17.5761.17 29.961.94 4662.2 p,0.0001
PAS (mm of Hg) 21.062.19 45.263.67 71.6765.5 p,0.0001
PAD (mm of Hg): 11.061.39 19.462.1 29.5860.85 p,0.0001
RA (mm of Hg) 5.5761.77 7.060.96 10.561.44 p,0.05
PVR (dyn*.s*.cm25) 105.6624.64 280.3653.74 508.4662.73 p,0.0001
RVSP (mm of Hg) 30.33610.17 59.2966.83 75.666.83 p,0.05
RVID (cm) 2.9260.24 3.9860.35 3.7360.24 p,0.05
EF (%) 56.1462.20 57.9261.99 54.562.5 p = n.s
P,0.0001 was observed for PAM, PAS and PAD, p = 0.058 for RA, p = 0.0002 for
RVR, p = 0.0007 for RVSP, p = 0.088 for RVID and p= n.s for EF.
doi:10.1371/journal.pone.0064396.t001
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comparative analysis in between the groups (moderate and severe
PH human subjects) with those of healthy control subjects.
Results
Patient characterization and evaluation
We have included mean pulmonary artery pressure (mPAP),
right atrial pressure (RA), pulmonary vascular resistance (PVR),
pulmonary artery systolic pressure (PAS) and pulmonary artery
diastolic pressure (PAD) for moderate-to-severe PH in human
subjects. Our data showed that mPAP, PAS and PAD were
significantly increased in the PH patients compared to the controls
(Fig. 1A). Additionally, we observed that the RA, pulmonary
vascular resistance (PVR), right ventricular systolic pressure
(RVSP) and right ventricular internal diameter (RVID) were
significantly increased compared to the control subjects (Fig. 1B).
It is of note that above functional parameters were increased as the
disease progressed or the severity (Fig. 1). The detail analysis of the
above parameters are shown below in the table 1
PH induces changes in miRNA profile in circulation
This is the first report where we observed differential miRNA
expression in patients with PH and compared with healthy
individuals who did not show the mean arterial pressure greater
than 25 mm of Hg by miRNA microarray. We observed that
several miRNAs were differentially expressed in the PH patients
compared to control subjects (Figure 2). The data analysis package
from LC Sciences was used to prepare data-rich volcano plots
between, which show p-value and fold-change between two groups
for all miRNAs. Color and spot diameter depicted information
about mean expression level and percent detected, respectively in
the heat maps (Figure 2). The arrays were based on Sanger miR
Base release 18.0 databases. For two-color experiments, the ratio
of the two sets of detected signals (log2- transformed, balanced) and
the p values of the t-test were calculated.
We validated a set of miRNAs in our cohort study. We choose
the following miRNAs for validation:
MiR-21, miR-23a, miR-26a, miR-29, miR-34b, miR-191, miR-
451 and miR-1246 were derived from the miRNA array analysis
(Figure 2). We also have included few cardiac specific miRNAs
(e.g. miR-1, 133b and 208b) as to test whether they are circulating
in PH subjects. Furthermore, we included another miRNA which
was reported to be involved in PH (e.g. miR-204). Finally, we
tested two other miRNAs which had target genes that were
associated with PH. These miRNAs are miR-30b which has target
for Notch1 and Bcl2 and, miR-130a has target for BMPR1b and
SMAD2. It is of note that these miRNAs were not detected in the
miRNA array possibly because of low level of detection limit.
MiR-1, miR-26a, miR-29c, miR-34b, miR-451 and miR-1246
are downregulated in PH subjects
We determined the expression of circulatory miRNAs in
control, moderate PH and severe PH subjects. The expressions
of miR-26a, miR-29c, miR-451 and miR-1246 were declined to
0.6660.12, 0.5260.14, 0.4960.16 (p,0.05) and 0.6760.21-folds
(p = ns) respectively, in moderate PH subjects, compared to the
control subjects. The expressions of the above miRNA were
further declined to 0.4960.18, 0.4260.14, 0.3460.14 and
0.3660.17-fold respectively (p,0.05), in severe PH subjects,
compared to the control subjects (Fig. 3A and 3B). The expression
of miR-34b and miR-1 showed strongest declined pattern among
the PH subjects. The expression of miR-34b was 0.3460.1 and
0.1260.08 (p,0.05) in moderate and severe PH respectively,
compared to the control counterparts. The expression of miR-1
showed 0.2760.06-fold in moderate PH and elicited a sharp
decline to 0.1360.05-fold (p,0.05) in severe PH subjects,
compared to the control subjects (Fig. 3 B). The expression of
the above miRNAs was not significant when compared the values
between moderate vs. severe PH.
Mi-130a, mir-133b, miR-191, miR-204 and miR-208b are
highly elevated in PH subjects
The expression of miR-130a, miR-133b and miR-191 were
increased significantly in all PH subjects and, showed further
pronounced in severe PH subjects. The expression of miR-130a
showed a 2.5460.56-fold (p,0.05) enhancement in moderate PH
where severe PH showed a sharp increment of 9.2761.19-fold
(p,0.01), respectively. In moderate PH subjects, the expression of
miR-133b was 2.7061.07-fold and 3.9661.63-fold (p = ns) in
moderate and severe PH subjects, compared to the control
subjects. Likewise, in the moderate PH group, the expression of
miR-191 was 2.8860.71-fold and was further increased to
5.8361.66-fold (p,0.05) in severe PH subjects, compared to the
controls (Fig. 4A). The expression of miR-204 was increased to
4.4261.29-fold (p,0.05) in the moderate PH subjects and was
further elevated to 7.4863.8 fold (p,0.01) in severe PH subjects,
compared to their controls (Fig. 4B). The expression of miR-208b
was 1.4460.35 (p = ns) in moderate PH subjects and was
5.6261.46 (p,0.05) in severe PH subjects, compared to their
controls (Fig. 4B). It is of note that the expression of miR-133b,
miR-191 and miR-204 were not significant in severe PH subjects,
compared to their moderate counterparts. However, the expres-
sion of miR-130a and miR-208b were significant in severe PH
subjects, compared to their moderate counterparts.
MiR-21, miR-23b and miR-30b are moderately elevated in
PH subjects
The expression of miR-21 and miR-23b were moderately
increased in all PH subjects but showed more pronounced in
severe PH subjects. In moderate PH subjects, the expression of
miR-21 was 2.460.36-fold and 3.0960.71-fold (p,0.05) in severe
PH subjects, compared to the control subjects. Likewise, in the
moderate PH group, the expression of miR-23b was 2.3960.76-
fold (p,0.05) and 4.0760.88-fold (p,0.01) increased in severe PH
subjects, compared to the controls (Fig. 4B). The expression of
miR-30b was 1.5460.22-fold (p,0.05) and 3.5860.63-fold -folds
(p,0.01) in moderate and severe PH, respectively (Fig. 4 B). It is of
note that the expression of miR-23b and miR-30b but, not the
miR-21, were significant in severe PH subjects; compared to their
moderate counterparts.
Influence of gender in miRNA expression in PH subjects
In order to determine whether gender has any influence in
circulatory miRNA expression, we determined all validated
miRNAs as gender based cohort study. We compared the miRNA
expressions pattern in male and female PH subjects separately;
and both the genders (Fig. 5). Among the downregulated miRNAs;
miR-1, miR-29c, and miR-34b showed more declined expression
in the female subjects, compared to the male counterpart. In
contrast miR-451 and miR-1246 showed sharp declined expres-
sion in the male subjects (Fig. 5). The miR-26a did not show any
significant pattern of changes between male and female subjects.
Likewise, among upregulated miRNAs, miR-23b and miR-30b
showed more incremental expression in the male subjects,
compared to the female subjects. In contrast, miR-21, miR-
133b, miR-191and miR-208b showed enhanced expression in the
female subjects, compared to the male counterpart (Fig. 5). The
Circulatory miRNAs in Pulmonary Hypertension
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Figure 2. Heat map showing the expression of dysregulated miRNAs in control and PH human subjects. MiRNA microarray data was
prepared using data from the miRNA microarray performed using samples from PH human patients and compared with healthy controls. The signal
difference (log2) is plotted versus the level of statistical significance (2log10 p-value). Color and spot diameter depicted information about mean
expression level and percent detected, respectively, in static plots.
doi:10.1371/journal.pone.0064396.g002
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expression of miR-130a and miR-204 did not show any significant
pattern changes among the male and female subjects, compared to
their total expression. The severity of PH did not show any
significant influence between the male and female subjects.
Discussion
The present study for the first time demonstrates that PH
induces novel circulatory miRNA derived from human PH
subject. Recent evidences indicate that freely circulating miRNAs
may be informative in the diagnostic setting and have the potential
to be used as biomarkers. Our study demonstrates that in human
subjects with diverse clinical settings in PH are associated with
distinct dysregulation of miRNAs in the circulation. It is of note
that PH is associated with other diseases like COPD, scleroderma,
obstructive lung diseases, etc, and, may therefore, consider as an
idiopathic type. However, our data are consistent with respect to
mPAP elevation and severity of PH which is the hallmark for PH.
The observation may provide early detection of PH in human
serum.
Our study reveals that in human subjects with moderate to
severe PH are associated with significant downregulation of
plasma levels of circulatory miR-1, miR-26a and miR-29c. The
kinetics of the changes differed from moderate to severe PH
human subjects as we observed further downregulation of the
above miRNAs in severe PH. Targetscan analysis showed that
miR-26a and miR-29c had target genes for collagens which
involved in pro-fibrotic events and fibrosis. It is of note that the
patient population include in this study suffered from lung fibrosis,
interstitial lung disease and, RVH that lead to cardiac fibrosis. The
miR-1 has target genes for Notch3 which is upregulated in PH in
human as well as in rat model may indicate a functional
correlation [26]. Likewise, miR-29 family directly target at least
16 extracellular matrix genes, providing a strong evidence for anti-
fibrotic effects in related organs including heart [27]. TargetScan
and PicTar analysis showed that miR-26a showed target for
collagen type I and CTGF gene and miR-451 showed target for
titin which are markers for pro-fibrotic process. The miR-1246
showed target for caveolin1, GSK3ß and cadherin 2 genes.
Together, our data indicate a possibility of functional correlation
between the circulatory miRNA and distant organ dysfunction.
The reduction of these miRNAs in circulation are surprising as we
expect that either endothelial or cardiac cell activation, the
miRNAs should be shedding off as microparticle or apoptotic
bodies, thereby, elevating the level in circulation [18,19,20,21]. A
Figure 3. Real time-PCR based validation of downregulated
miRNAs in the buffy coat of healthy human subjects vs. PH
patients. A. Expression of miR-1, miR-26a and miR-29c B. Expression of
miR-34b, miR-451 and miR-1246. Data represent means 6 SEM. N= 16
for control, 15 for moderate PH and 17 for severe PH group. *denotes
p,0.05 and ** denotes p,0.01 compared to the healthy subjects.
doi:10.1371/journal.pone.0064396.g003
Figure 4. Real time-PCR based validation of upregulated miRNAs in the buffy coat of healthy human subjects vs. PH patients. A.
Expression of miR-21 and miR-23a, B. Expression of miR-30b and miR-130a, C. Expression of miR-133b and miR-191, D. Expression of miR-204 and
miR-208b. Data represent means6 SEM. N= 16 for control, 15 for moderate PH and 17 for severe PH group. *denotes p,0.05 and ** denotes p,0.01
compared to the healthy subjects.
doi:10.1371/journal.pone.0064396.g004
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recent analysis indicated that miRNAs can be transferred from
cell-to-cell by lipid-based carriers and affect gene expression or can
be delivered by apoptotic bodies [21,28]. Therefore, we can
speculate the attenuation of these miRNAs might be taken up by
the damaged vessels and elicit less abundant in the circulation.
Our data indicated a set of upregulated miRNA in the
circulation of PH subjected compared, to the controls. During
moderate PH, miR-21, miR-23b, miR-130a, miR-491 and miR-
1246 are moderately upregulated but, are more pronounced in
severe PH, compared to the controls. Our data also revealed
another set of miRNAs that include miR-133b, miR-204 and
miR-208b which were significantly upregulated in all moderate
PH subjects but, showed further increment in severe PH subjects.
Among them, miR-208b and miR-133b are considered to be
cardiac specific suggesting that they may be released from the
injured non-cardiac muscles [29,30,31,32]. The upregulation of
miRNA appears to have some functional relevance when analyzed
through TargetScan, MiroCosm or PicTar databases. Interesting-
ly, miR-23b and miR-130a showed target genes for BMPR1b
which is degraded during PH and considered as a predictor for PH
[33,34]. Our recent data support this observation where we
showed downregulation of BMPR1b, Id1, Id3 and Smad2 in
monocrotaline induced mouse PH model [35], but, the functional
correlation between the circulatory miRNA and tissue level
expression has not been determined. Likewise, the potential role
of miR-21 has been defined in few recent studies in PH and
vascular remodeling [36,37,38]. The expression of miR-21 has
been demonstrated to be downregulated in mouse model or in
human subjects. Moreover, in a recent study by Courboulin A et al
showed the downregulation of miR-204 in human PH subjects and
in experimentally induced PH rat model and discovered a new
regulatory pathway involving miR-204, which was critical to the
etiology of PH. The study showed that delivery of synthetic miR-
204 to the lungs of animals with PH significantly mitigated disease
severity [39]. Our data corroborated with the finding of
upregulation of both miR-21 and miR-204. The upregulation of
these miRNAs can be explained by the release from injured vessels
into circulation. It may be speculated that miRNAs may leak into
the blood stream during injury and are steadily present as an
elevated level in the circulation. The biological correlation
between circulatory miRNA and the distant organ expression
has not been established and warrants further investigation.
However, it was reported that after drug-induced liver injury,
miRNAs elevated in plasma were consistently downregulated in
corresponding liver suggesting the intriguing possibility of a
cellular survival mechanism in which, during stress, undesirable
miRNAs are actively excreted [15]. A recent study further suggests
that miRNA can be produced by one cell type in a different organ
and, can be transported like hormones to the effector site for
action [40]. Therefore, it is reasonable to speculate that these
miRNAs are released either form the RV or the damaged lungs or
vessels due to elevated PH. Interestingly, we observed a variation
of few dysregulated miRNAs in the male and female subjects
which opens a new avenue whether gender has any influence in
the degree of expression in the circulation.
Figure 5. Effect of gender on dysregulated miRNAs miRNAs were detected in the validation cohort of PH by RT-PCR and was
normalized using has-U6 housekeeping gene. Data represent means 6 SEM, n = 12–15 for female PH subjects and n= 10–12 for male PH
subjects.
doi:10.1371/journal.pone.0064396.g005
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Together, these data indicated a potential use of these miRNAs
as an early detection biomarker of PH. From this study, we present
evidence that a set of increased plasma miRNA level that include
miR-21, miR-130a, miR-133b, miR-191, miR-204 and miR-
208b, can be used as biomarker for assessment of PH. On the
contrary, our data revealed a set of declined miRNAs which
includes miR-26a, miR-29c, miR-34b and miR-451and; can be
used as biomarker as well. These findings are of vital importance
for the diagnostic applicability of plasma miRNAs in clinical
settings and in particular, where altered distributions of biomark-
ers, combined with co-morbidities such RVH, pulmonary fibrosis,
are common. Alternatively, the significant decrease of miR-1,
miR-26a and miR-29c level in PH has potential diagnostic
significance.
In summary, the current study provides for the first time the
detection of circulatory miRNAs in PH human subjects. We report
that initial PH induced damage of endothelial cells marked by
increased mPAP and RA initiates dysregulation of miRNAs in the
organ or tissue architecture which then shedding off and, come
into the circulation. Our study suggests that a specific set of
dysregulation (up- and down regulation) of miRNAs originating
from either cardiac or vascular bed can be detected in the
circulation. Our study includes a diverse PH cohort, but, it is noted
that all subjects are diagnosed with PH. We, therefore, assume that
changes of miRNA in circulation are primarily due to elevated
PH. The dysregulation of these miRNAs may serve as therapeutic
target for drug invention or early diagnostic tool for PH, PH
induced RVH and interstitial lung disease. Further experimental
studies are required to define the synergistic association between
the tissue expressions versus circulation in patient population.
Although circulatory miRNA offers a great potential for the
diagnosis; however, precise quantification, normalization and
larger cohort studies are warranted. These parameters are
necessary for accurately translating the findings into clinical
biomarkers.
Limitation of the study
Our study provides the first evidence of circulating miRNAs in
the setting PH may use as an early detection for PH. Nevertheless,
the data presented here are based on limited study population and,
the results need to be confirmed in a larger cohort study.
Furthermore, the dysregulation miRNA in PH remains to be
tested whether these circulatory miRNAs have any influence in the
target genes. Elucidating the possible biological role of PH specific
miRNAs in the circulation is beyond the scope of this study.
However, considering the recent reports describing cell-to-cell
transport of miRNAs [41] and miRNAs as paracrine signaling
molecules [21], one might speculate that the presence of miRNAs
in circulation is not merely a by-product of tissue damage, but also
implies a functional role for these molecules.
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